Giredestrant combination significantly improved PFS in ER-positive advanced breast cancer in Ph 3 evERA; data published in The NEJM October 6, 2026
$92.5M Series E Financing to Advance First-in-class Cyclin D1 Program CID-615 into Clinical Development Announced September 22, 2026
Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development September 22, 2026
FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer September 22, 2026
Enhertu recommended for approval in the EU by CHMP as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer September 22, 2026
FDA clears IND application to initiate Ph 1 study for PRT13722 for HR+/HER2- breast cancer patients September 16, 2026
FAILED TRIAL: SERENA-4 trial of Etcamah + palbociclib did not meet primary objective of statistically significant PFS improvement September 16, 2026
Results from Ph 3 Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO September 16, 2026
AIM ImmunoTech Secures Broad US Patent for Rintatolimod (Ampligen®) Used in Combination with Keytruda, Expanding Oncology IP Protection for Ampligen Through 2039 September 9, 2026
Etcamah + CDK4/6 inhibitor combo approved in the US for 1L advanced HR-positive breast cancer September 9, 2026
Supplemental NDA submitted to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer September 2, 2026
FDA Fast Track Designation for ETX-19477 for the Treatment of Patients with BRCA-Mutated, HR+/HER2- Unresectable or Metastatic Breast Cancer August 25, 2026
Vepdegestrant Now Available for U.S. Patients With ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer August 20, 2026
Evexta Bio and Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced/Metastatic Breast Cancer August 11, 2026
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the NCCN Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer August 5, 2026
Datroway approved in the EU for 1L metastatic TNBC patients not candidates for immunotherapy August 5, 2026
Enhertu + pertuzumab recommended for approval in the EU by CHMP in 1L HER2-positive metastatic breast cancer July 28, 2026
BeOne Medicines Expands U.S. Manufacturing with More Than $1 Billion Investment to Advance Cancer Medicines July 28, 2026
